Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash & Equivalents (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Cash & Equivalents for 17 consecutive years, with $149.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 46.09% to $149.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.6 million through Dec 2025, up 46.09% year-over-year, with the annual reading at $149.6 million for FY2025, 46.09% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $149.6 million at Myriad Genetics, up from $145.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $295.2 million in Q3 2021, with the low at $53.6 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $123.6 million, with a median of $103.5 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents soared 149.54% in 2021, then crashed 77.89% in 2022.
  • Over 5 years, Cash & Equivalents stood at $257.4 million in 2021, then plummeted by 77.89% to $56.9 million in 2022, then surged by 132.16% to $132.1 million in 2023, then decreased by 22.48% to $102.4 million in 2024, then surged by 46.09% to $149.6 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $149.6 million, $145.4 million, and $74.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.